INFRA develops AI algorithmic models that detect weak signals to assess medical risk and predict the occurrence of health-related events. By focusing on early detection, particularly in breast cancer, the company aims to enhance preventive care and improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for assessing medical risk often fail to detect subtle indicators, leading to delayed diagnoses and reactive treatment approaches, particularly in diseases like breast cancer. This can result in poorer patient outcomes and increased healthcare costs.
Solution
INFRA develops AI algorithmic models designed to detect weak signals and subtle patterns in medical data to assess medical risk and predict health-related events. By focusing on early detection, INFRA aims to enable proactive and preventive care strategies. Their technology is designed to identify early indicators of disease, allowing for timely intervention and improved patient outcomes. The company's initial focus is on enhancing breast cancer detection through AI-driven analysis of medical data.
Target Audience
INFRA's primary target audience includes healthcare providers, medical researchers, and organizations focused on improving patient outcomes through early disease detection and preventive care.
Features
- AI algorithmic models for detecting weak signals in medical data
- Predictive analytics for assessing medical risk and anticipating health events
- Focus on early detection to enable proactive care
- Application of AI to enhance breast cancer detection